-
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert PanelD Capodanno, MC Morice, DJ Angiolillo et al. -
Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCIHY Wang, RL Gao, KF Dou et al.
-
A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of theKedhi E, Fabris E, van der Ent M et al.
-
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary InterventionDJ Angiolillo, U Baber, R Mehran et al.
-
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical PerspectiveG Tersalvi, L Biasco, GM Cioffi et al.
-
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trialJ Silvain, B Lattuca, ALPHEUS investigators et al.
-
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCIK Takahashi, PW Serruys, P Chichareont et al.
-
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS RegistryJoyce LC, Baber U, Mehran R et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
